M&A / Deals BioMarin acquires Amicus Therapeutics for $4.8bn Pharmaceutical TechnologyBioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.Rare DiseaseRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaceutical Technology BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA approves AstraZeneca’s Saphnelo for SLENext: Boehringer/Zealand dual-acting drug causes 16.6% weight loss Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
